De-risking money

Cleave Bioscience Inc.'s investors allowed New Enterprise Associates to add $10 million last week on the same terms as a 2011 A round because the lion's share of money and de-risking is tied to human testing of its next generation proteasome pathway inhibitors, which is still at least 18 months away. The original investors committed $44 million in the tranched round.